Literature DB >> 9916943

Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products.

M P Martegani1, F Del Prete, A Gasbarri, P G Natali, A Bartolazzi.   

Abstract

CD44 can be considered structurally and functionally one of the most variable surface molecules. Alternative splicing of variant exons as well as posttranslational modifications of the molecule (differences in glycosylation) generate a rich repertoire of CD44 isoforms (CD44v), some of which seem to play a key role in tumor growth and progression. Immunodetection of CD44 isoforms in vivo, using mAbs specific for CD44 variant exon products, is largely used to identify those CD44 molecules involved in tumor growth and progression and to interfere with CD44-mediated processes. In the present work we demonstrate that the immunoreactivity of some mAbs directed to CD44 exon-specific epitopes can be impaired by the structural variability of the molecule. Our findings demonstrate that (1) specific exon assortment and/or posttranslational modifications of CD44v molecules can mask CD44 exon-specific epitopes; (2) glycosaminoglycan side chains, carried by some CD44v isoforms of high molecular weight, may play a critical role in determining the exact conformation of the molecule, which is necessary for the detection of CD44 variant epitopes by specific mAbs; and (3) in a panel of stable transfectants expressing CD44 N-glycosylation site-specific mutants, generated in the constant region of CD44 extracellular domain, asparagine-isoleucine substitution is sufficient per se to impair the immunoreactivity of several mAbs to pan-CD44. Thus, conformational changes due to the alternative splicing of CD44 variant exons and/or posttranslational modifications of the molecule (different degree of glycosylation), which are cell type-specific, are likely to generate CD44 variants that elude immunodetection. These findings strongly suggest that immunohistochemical analysis of CD44 expression in vitro and in vivo, using mAbs specific for CD44 variant exon epitopes, can potentially be impaired by a large number of false negative results.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916943      PMCID: PMC1853452          DOI: 10.1016/S0002-9440(10)65275-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain.

Authors:  D G Jackson; J Buckley; J I Bell
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

2.  New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues.

Authors:  D J Anstee; B Gardner; F A Spring; C H Holmes; K L Simpson; S F Parsons; G Mallinson; S M Yousaf; P A Judson
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

3.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  CD44 is the principal cell surface receptor for hyaluronate.

Authors:  A Aruffo; I Stamenkovic; M Melnick; C B Underhill; B Seed
Journal:  Cell       Date:  1990-06-29       Impact factor: 41.582

5.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

6.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

7.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44.

Authors:  R Arch; K Wirth; M Hofmann; H Ponta; S Matzku; P Herrlich; M Zöller
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

9.  Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.

Authors:  A Bartolazzi; R Peach; A Aruffo; I Stamenkovic
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

10.  Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein.

Authors:  M S Sy; Y J Guo; I Stamenkovic
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

View more
  11 in total

1.  Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications.

Authors:  H S Berner; B Davidson; A Berner; B Risberg; G B Kristensen; C G Trope; G Van de Putte; J M Nesland
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Transferrin D protein variants in the diagnosis of congenital disorders of glycosylation (CDG).

Authors:  Eliska Marklová; Ziad Albahri
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Alterations in human breast cancer adhesion-motility in response to changes in cell surface glycoproteins displaying alpha-L-fucose moieties.

Authors:  Kun Yuan; Dennis Kucik; Raj K Singh; Catherine M Listinsky; Jay J Listinsky; Gene P Siegal
Journal:  Int J Oncol       Date:  2008-04       Impact factor: 5.650

4.  Microparticle Delivery of Protein Markers for Single-Cell Western Blotting from Microwells.

Authors:  John J Kim; Peggy P Y Chan; Julea Vlassakis; Alisha Geldert; Amy E Herr
Journal:  Small       Date:  2018-10-17       Impact factor: 13.281

5.  CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.

Authors:  Abirami Rajarajan; Angela Stokes; Balvinder K Bloor; Rebecca Ceder; Hemini Desai; Roland C Grafström; Edward W Odell
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

6.  Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Authors:  V Veschi; M Petroni; A Bartolazzi; P Altavista; C Dominici; C Capalbo; R Boldrini; A Castellano; H P McDowell; B Pizer; L Frati; I Screpanti; A Gulino; G Giannini
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

7.  Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic implications.

Authors:  Lucia Spath; Alessandra Ulivieri; Luca Lavra; Laura Fidanza; Marta Carlesimo; Maria Giubettini; Alessandra Narcisi; Emidio Luciani; Barbara Bucci; Daniela Pisani; Salvatore Sciacchitano; Armando Bartolazzi
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

8.  Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance.

Authors:  K A Whelan; P M Chandramouleeswaran; K Tanaka; M Natsuizaka; M Guha; S Srinivasan; D S Darling; Y Kita; S Natsugoe; J D Winkler; A J Klein-Szanto; R K Amaravadi; N G Avadhani; A K Rustgi; H Nakagawa
Journal:  Oncogene       Date:  2017-04-17       Impact factor: 9.867

Review 9.  Cardiovascular Effects Mediated by HMMR and CD44.

Authors:  Kinga Jaskuła; Mariusz Sacharczuk; Zbigniew Gaciong; Dominik S Skiba
Journal:  Mediators Inflamm       Date:  2021-07-10       Impact factor: 4.711

10.  The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.

Authors:  Kento Tsubouchi; Kazumasa Minami; Naoki Hayashi; Yuhki Yokoyama; Seiji Mori; Hirofumi Yamamoto; Masahiko Koizumi
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.